Moderna, prominent producer of mRNA technology showed a decrease in its stock value by 9.6% following an adjustment in its 2025 sales projection and halting its
CMV Vaccine Program. Despite this setback, Moderna posted indicators of positive growth after its
Q3 earnings exceeded estimations and demonstrated promising results from the
mRNA flu vaccine trial. Renewed scrutiny has arisen over Moderna's pediatric vaccine safety impacting the company's investment narrative. However, Moderna has recently received
FDA approval for its COVID vaccine for high-risk children under the age of 12. Notably, Moderna's combo COVID and flu mRNA shot outperformed current vaccines in large trials, indicating potential dominance in the market moving forward. Amidst these developments, Moderna received a cut in price target from analysts at Bank of America while RFK Jr cancelled mRNA research funding. On the other hand, this comes with news of a $590 million award from HHS to Moderna to develop mRNA vaccines against pandemic flu threats, igniting possible future revenue streams. However, Moderna's journey in mRNA technology has been fraught with challenges, including HHS's misleading statements on mRNA vaccine safety and halting financing for its bird flu vaccine.
Moderna MRNA News Analytics from Fri, 17 Jan 2025 08:00:00 GMT to Fri, 14 Nov 2025 15:00:35 GMT -
Rating 2
- Innovation 8
- Information 7
- Rumor -1
